More Stories

Informist, Wednesday, Nov. 5, 2025

 

Please click here to read all liners published on this story

--Sun Pharma Jul-Sept consol net profit INR 31.18 bln 
--Analysts saw Sun Pharma Jul-Sept consol net profit at INR 29.44 bln
--Sun Pharma Jul-Sept consol revenue INR 144.78 bln
--Analysts saw Sun Pharma Jul-Sept consol revenue at INR 142.51 bln
--Sun Pharma Jul-Sept consol net profit INR 31.18 bln vs INR 30.40 bln yr ago
--Sun Pharma Jul-Sept consol revenue INR 144.78 bln vs INR 132.91 bln yr ago
--Sun Pharma Apr-Sept consol net profit 53.97 INR bln vs INR 58.76 bln yr ago
--Sun Pharma Apr-Sept consol revenue INR 283.30 bln vs INR 259.44 bln yr ago
--Sun Pharma Jul-Sept consol EBITDA INR 45.27 bln, up 14.9% on year
--Sun Pharma Jul-Sept consol EBITDA margin 31.3%
--Sun Pharma Q2 India formulation sales INR 47.35 bln, up 11% on year
--Sun Pharma Q2 US formulation sales $496 mln, down 4.1% on year
--Sun Pharma Q2 India formulation sales were 32.9% of consol sales
--Sun Pharma Q2 US formulation sales were 30.1% of consol sales
--Sun Pharma Q2 emerging mkt formulation sales $325 mln, up 10.9% on year
--Sun Pharma Q2 emerging mkt formulation sales were 19.7% of consol sales
--Sun Pharma Q2 Rest of World formulation sales $234 mln, up 17.7% on year
--Sun Pharma Q2 API external sales INR 4.30 bln, down 19.5% on year
--Sun Pharma Jul-Sept consol R&D spend INR 7.83 bln, 5.4% of sales
--Sun Pharma Q2 global innovative medicine sales $333 mln, up 16.4% on year
--Sun Pharma Q2 global innovative medicine sales were 20.2% of consol sales
 

 

By Sunil Raghu

 

AHMEDABAD – Sun Pharmaceutical Industries Ltd.'s top line for the September quarter rose more than expected on the back of strength in sales of formulations in India, emerging markets, and rest of the world. The company has now recorded on-year growth in its revenue for the twentieth consecutive quarter. It also saw a minor dip in the cost of raw materials consumed. This helped the company return to growth in its consolidated profit after it fell for two successive quarters.

 

Sun Pharmaceutical Wednesday reported a consolidated net profit of INR 31.18 billion for Jul-Sept, up nearly 3% on year. Its revenue from operations rose nearly 9% on year to INR 144.78 billion. Analysts had projected Sun Pharmaceutical's September quarter net profit at INR 29.4 billion on revenue of INR 142.5 billion.

 

Sun Pharmaceutical reported a 4.1% on-year drop in US formulation sales in the September quarter at $496 million, it said in a press release. US formulations account for 30.1% of the company's total sales. The company's global specialty product sales, which account for nearly 20.2% of the total sales, were up 16.4% on year at $333 million.

 

"India, Emerging Markets and Rest of World led our growth for the period. US sales of innovative medicines have surpassed generics for the first time during the quarter," Managing Director Kirti Ganorkar was quoted as saying in the press release. "We remain focused on broadening our portfolio while strengthening in-house talent pool and execution capability."

 

For India formulation sales, which account for 32.9% of the total consolidated sales, the company reported an 11% rise on year at INR 47.35 billion. Emerging markets formulation sales rose 10.9% on year to $325 million, and rest-of-the-world formulation sales were up 17.7% on year at $234 million. The company's active pharmaceutical ingredient sales for external clients during the September quarter were down 19.5% on year at INR 4.30 billion.

 

Sun Pharmaceutical reported an earnings before interest, tax, depreciation, and amortisation margin of 31.3% for the September quarter. Its EBITDA was up 14.9% on year at INR 45.27 billion. According to the average of estimates from 11 brokerages, the company's EBITDA for the September quarter was pegged at INR 41 billion. The EBITDA margin was expected to fall 200 basis points on quarter to 27.4%.

 

Brokerages had estimated Sun Pharmaceutical's research and development expenditure at 7% of sales, up 70 bps on quarter. The company's spending on R&D during the quarter stood at INR 7.83 billion, around 5.4% of total sales. Sun Pharmaceutical said its R&D spending was focused on both the specialty and generic businesses and the company continues to invest in building the pipeline for various markets. Sun Pharmaceutical's specialty R&D pipeline includes six novel entities in the clinical trial stage, the company said.

 

Sun Pharma said it has a comprehensive product offering in the US market, consisting of approved abbreviated new drug applications, or ANDAs, for 548 products. Another 117 ANDAs are awaiting approval by the US drug regulator, which include 31 tentative approvals given. During the September quarter, Sun Pharma filed four ANDAs and received approval for five.

 

For Apr-Sept, Sun Pharma recorded a consolidated net profit of INR 53.97 billion, compared with INR 58.76 billion a year ago. Its consolidated revenue for the first six months of 2025-26 (Apr-Mar) stood INR 283.30 billion, compared to INR 259.44 billion a year ago.

 

On Tuesday, shares of Sun Pharmaceutical Industries ended nearly 1% lower at INR 1,690 on the National Stock Exchange.  End

 

US$1 = INR 88.66

 

Edited by Avishek Dutta

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

 

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.